Clinical trials: Plaque Psoriasis.
Crohn Disease, Plaque Psoriasis
ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
ROLL'YN-UST is a real-life study, which includes patients in clinical remission for at least 3 months and who have been treated with a reference biotherapy for at least 6 months, and for whom the physician has decided…
- Trial name
- ROLL'YN-UST (NCT06997055)
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- France
- Volunteers
- 225 people
- Sponsor
- Celltrion HealthCare France
Psoriasis
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
- Trial name
- N/Z (NCT07489885)
- Testing
- D-2570 Tablet
- Where
- 20 sites in United States
- Volunteers
- 75 people
- Sponsor
- InventisBio Co., Ltd
Plaque Psoriasis
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to <18 years with moderate to severe plaque psoriasis.
- Trial name
- NCT04772079
- Testing
- Deucravacitinib
- Where
- 65 sites in Argentina, Australia and 11 more
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for…
- Trial name
- NCT03875508
- Testing
- Risankizumab, Autoinjector
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- AbbVie
Plaque Psoriasis Vulgaris
Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
- Trial name
- DERMIS (NCT03310320)
- Testing
- AZD0284 oral solution 2.5 mg/mL
- Where
- 4 sites in Denmark
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Plaque Psoriasis
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
The main purpose of this study is to learn more about the safety and side effects of DC-806 when given by mouth to healthy participants and participants with Chronic Plaque Psoriasis. The study will have three parts.
- Trial name
- NCT06808815
- Testing
- DC-806
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03364309
- Testing
- Ixekizumab
- Where
- 17 sites in China
- Volunteers
- 438 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis
This is a randomized single-blind comparative parallel group efficacy and safety study of ustekinumab biosimilar GNR-068 (45 mg) and reference product Stelara® (45 mg) in the treatment of patients with moderate and severe forms…
- Trial name
- NCT06488664
- Testing
- GNR-068, Stelara®
- Where
- 34 sites in Russia
- Volunteers
- 422 people
- Sponsor
- AO GENERIUM
Psoriasis
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- X-PLORE (NCT01483599)
- Testing
- CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg)
- Where
- 40 sites in United States, Belgium and 3 more
- Volunteers
- 293 people
- Sponsor
- Janssen Inc.
Psoriasis
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to…
- Trial name
- NAVIGATE (NCT02203032)
- Testing
- Ustekinumab, Guselkumab
- Where
- 85 sites in United States, Australia and 8 more
- Volunteers
- 872 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in…
- Trial name
- NCT00096603
- Testing
- Raptiva (efalizumab)
- Volunteers
- 450 people
- Sponsor
- Genentech, Inc.
Psoriasis
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT01970488
- Testing
- Adalimumab, ABP 501
- Where
- 3 sites in Australia, Canada and 1 more
- Volunteers
- 350 people
- Sponsor
- Amgen
Plaque Psoriasis, Psoriasis (PsO)
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: How safe is taking ESK-001 long-term in people with moderate to…
- Conditions
- Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
- Trial name
- ONWARD3 (NCT06846541)
- Testing
- Open-Label Envudeucitinib, Blinded Envudeucitinib
- Where
- 268 sites in United States, Australia and 14 more
- Volunteers
- 1,680 people
- Sponsor
- Alumis Inc
Psoriasis
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.
- Trial name
- NCT01543204
- Testing
- Etanercept
- Where
- 47 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Amgen
Psoriasis
Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test
The aim of the exploratory study is to compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT).
- Trial name
- NCT01360944
- Testing
- LAS41004, reference
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.
- Trial name
- NCT02749799
- Testing
- DFD-01 (betamethasone dipropionate) Spray, 0.05%
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis
KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis
This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 in the treatment of patients with plaque-type psoriasis.
- Trial name
- NCT05522816
- Testing
- KX01 0.01% (0.1 mg/g), KX01 0.1% (1.0 mg/g), KX01 1% (10 mg/g) for 5 days
- Volunteers
- 28 people
- Sponsor
- PharmaEssentia
Psoriasis
Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
efficacy study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206387
- Testing
- Desoximetasone Spray 0.25%
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis
- Trial name
- NCT02407041
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Galectin Therapeutics Inc.
Plaque Psoriasis
Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients
M5181 - a novel vitamin D3 analogue - is currently under development for the treatment of plaque psoriasis and is being developed as a topical ointment formulation (M518101) Clinical and non-clinical studies indicate that M5181…
- Trial name
- NCT01989429
- Testing
- M518101
- Where
- 6 sites in Austria, Bulgaria and 4 more
- Volunteers
- 788 people
- Sponsor
- Maruho Europe Limited